Skip to main content
. 2022 Nov 17;2022(11):CD014963. doi: 10.1002/14651858.CD014963.pub2

4.1. Analysis.

4.1

Comparison 4: Subgroup analysis: female versus male for the comparison of systemic corticosteroids versus standard care (plus/minus placebo) for hospitalised individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19, Outcome 1: All‐cause mortality up to 30 days